Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.73 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363365 | 1.00 | ALOX5 (0.73) | ALOX5BACE1ABCB1PTGS1PTGS2 | |
| SCHEMBL9791239 | 0.83 | ALOX5 (0.52) | ALOX5BACE1ABCB1PTGS1PTGS2 | |
| SCHEMBL9791238 | 0.83 | ALOX5 (0.52) | ALOX5BACE1ABCB1PTGS1PTGS2 | |
| SCHEMBL9791012 | 0.80 | NPY2R (0.51) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9791006 | 0.80 | NPY2R (0.51) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9791105 | 0.80 | ALOX5 (0.49) | ALOX5BACE1PTGS1PTGS2ITGB2 | |
| SCHEMBL11793495 | 0.80 | ALOX5 (0.62) | ALOX5BACE1ABCB1ITGB2ICAM1 | |
| SCHEMBL9791169 | 0.79 | ALOX5 (0.48) | ALOX5PTGS1PTGS2 | |
| SCHEMBL9791045 | 0.79 | ALOX5 (0.48) | ALOX5PTGS2 | |
| SCHEMBL9791218 | 0.79 | ALOX5 (0.48) | ALOX5BACE1PTGS1PTGS2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-5028629-A | 2-(Substituted)-N-Hydroxy-N-Alkylcinnamamides | ELI LILLY AND COMPANY (US) | 1991-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | ALOX5 3876/4885BACE1 337/4885ABCB1 713/4885 |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885BACE1 3794/4885ABCB1 238/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | ALOX5 2969/4885BACE1 1542/4885ABCB1 1291/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | ALOX5 25/4885BACE1 3794/4885ABCB1 238/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | ALOX5 10/4885BACE1 3842/4885ABCB1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.